Good Vita / The learning library

Plecanatide

A peptide analogue of uroguanylin that activates intestinal guanylate cyclase-C.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Approved medicines Human trials in product label Digestive health

Also discussed as: Trulance

What it is and how it works

Plecanatide is structurally related to uroguanylin and activates intestinal guanylate cyclase-C. The resulting signaling affects fluid secretion and bowel transit. A pathway description explains the research rationale but does not select a medicine for a person’s symptoms.

Source for the mechanism context →

A closer look at the cited evidence

Human trials in product label

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
DailyMed — Trulance mechanism and clinical studies
Design
Randomized placebo-controlled studies summarized in the label.
Who or what was studied
Adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.
What was observed
Trials evaluated bowel-movement outcomes and, where appropriate, abdominal symptoms.
Limits of interpretation
The evidence concerns defined adult diagnoses; it does not establish a broad digestive-health or pediatric use.
Read the cited study or assessment →

What the evidence means

The label reports trials in adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.

Approval and regulatory context

Trulance is approved for these defined adult conditions, not for a general digestive-health claim.

Safety and uncertainty

The label includes a pediatric dehydration boxed warning. Severe diarrhea and mechanical gastrointestinal obstruction are important safety considerations.

What remains uncertain

A similar mechanism does not make two medicines identical. Comparisons require direct evidence or careful examination of trial populations and outcomes, not a shared receptor name alone.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment